Universal pooled plasma (Uniplas®) does not induce complement-mediated hemolysis of human red blood cells in vitro

Transfusion and Apheresis Science

Volumn 52, Issue 1, 2015, Pages 128-135

  Heger, Andrea ^a   Brandstätter, Hubert ^a   Prager, Bettina ^a   Brainovic, Janja ^a   Cortes, Rhoda ^a   Römisch, Jürgen ^a  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

Author keywords

CIC; Functional assay; In vitro hemolysis; Soluble immune complexes; Uniplas; Universal plasma

Indexed keywords

BLOOD GROUP A ANTIBODY; BLOOD GROUP B ANTIBODY; OCTAPLAS; PLASMA SUBSTITUTE; UNCLASSIFIED DRUG; UNIVERSAL POOLED PLASMA; ALLOANTIBODY; ANTIGEN ANTIBODY COMPLEX; BLOOD GROUP ABO SYSTEM;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD GROUP; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; COMPLEMENT MEDIATED HEMOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOGLOBULIN AGGREGATE; IN VITRO STUDY; BLOOD; CHEMISTRY; CYTOLOGY; FEMALE; MALE; METABOLISM; PLASMA;

ABO BLOOD-GROUP SYSTEM; ANTIGEN-ANTIBODY COMPLEX; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; ISOANTIBODIES; MALE; PLASMA;

EID: 84926227641     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.04.039     Document Type: Article

References (28)

1. Stainsby D., Jones H., Asher D., Atterbury C., Boncinelli A., Brant L., et al. SHOT Steering group: serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006, 20:273-282.
2. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626.
3. Spalter S.H., Kaveri S.V., Bonnin E., Mani J.C., Cartron J.P., Kazatchkine M.D. Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. Blood 1999, 93:4418-4424.
4. Tinegate H.N., Davies T., Elshaw R.J., Jena G., Lyon M., Norfolk D.R., et al. When and why is blood crossmatches? A prospective survey of transfusion laboratory practice in two regions in the north of England. Vox Sang 2010, 99:163-167.
5. Fastman B.R., Kaplan H.S. Errors in transfusion medicine: have we learned our lesson?. Mt Sinai J Med 2011, 78:854-864.
6. Heddle N.M., Fung M., Hervig T., Szczepiorkowski Z.M., Torretta L., Arnold E., et al. Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). Transfusion 2012, 52:1687-1695.
7. Solheim B.G., Chetty R., Flesland I. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Haematol 2008, 15:612-617.
8. Olsson M.L., Clausen H. Modifying the red cell surface: towards and ABO-universal blood supply. Br J Haematol 2007, 140:3-12.
9. Nydegger U.E., Davis J.S. Soluble immune complexes in human disease. Crit Rec Clin Lab Sci 1980, 12:123-170.
10. Berger S., Balló H., Stutte H.J. Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro- and anti-inflammatory cytokines dependent on the antigen:antibody ratio. Eur J Immunol 1996, 26:1297-3001.
11. Lindorfer M.A., Hahn C.S., Foley P.L., Taylor R.P. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunol Rev 2001, 183:10-24.
12. Karamehic J., Subasic D., Kasumovic M., Hodzic H., Prljaca-Zecevici L., Tufekcic M., et al. Clinical management of patients with systemic lupus erythematosus (SLE) with different C1q-CIC and C3 concentrations. Med Arh 2010, 64:75-79.
13. Gilliam B.E., Reed M.R., Chauhan A.K., Dehlendorf A.B., Moore T.L. Significance of complement components C1q and C4 bound to circulating immune complexes in juvenile idiopathic arthritis. Clin Exp Rheumatol 2011, 29:1049-1056.
14. Sc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009, 97:219-225.
15. Lawrie A.S., Green L., Canciani M.T., Mackie I.J., Pewandi F., Scully M.A., et al. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang 2010, 99:232-238.
16. ®) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apher Sci 2006, 35:223-233.
17. ®) and a development product (Uniplas). Transfus Apher Sci 2007, 37:223-231.
18. ®) and in the universally applicable plasma (Uniplas) in development. Vox Sang 2007, 92:206-212.
19. ®. Vox Sang 2009, 97:226-233.
20. ® manufacturing - results from animal bioassay studies. Vox Sang 2012, 102:294-301.
21. ®) - rational and clinical properties. Thromb Res 2002, 107:33-37.
22. Tølløfsrud S., Noddeland H., Svennevig J.L., Bentsen G., Mollnes T.E., Solheim B.G. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intens Care Med 2003, 29:1736-1743.
23. Solheim B.G., Granov D.A., Juravlev V.A., Krawczyk M., Kubishkin V.A., Patutko U.I., et al. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 2005, 89:19-26.
24. Solheim B. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res 2006, 4:209-217.
25. Jilma-Stohlawetz P., Kursten F.W., Walasek C., Horvath M., Leitner G., List J., et al. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers. Transfusion 2011, 51:1228-1240.
26. Chekrizova V., Murphy W.G. Solvent/detergent plasma: use in neonatal patients, in adult and pediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 2006, 16:85-91.
27. Makino M., Fujiwara M., Watanabe H., Sugano H., Arakawa M. Evaluation of different preparations of aggregated human IgG for use as a standard in the assays of circulating immune complexes. J Clin Lab Immunol 1986, 21:151-157.
28. Stanilova S.A., Slavov E.S. Comparative study of circulating immune complex quantity detection by three assays - CIF-ELISA, C1q-ELISA and anti-C3 ELISA. J Immunol Methods 2001, 253:13-21.